Please login to the form below

Not currently logged in
Email:
Password:

Eli Lilly drug discovery initiative

Open collaboration between Eli Lilly and global laboratory researchers is the goal of the new Lilly Phenotypic Drug Discovery Initiative, known as PD2

Open collaboration between Eli Lilly and global laboratory researchers is the goal of the new Lilly Phenotypic Drug Discovery Initiative, known as PD2.

Through the venture, Alzheimer's disease, cancer, diabetes and osteoporosis will be targeted.

The scheme will use Lilly's disease-state assays and a secure web portal to evaluate the therapeutic potential of compounds synthesized in university and biotechnology laboratories. Its findings could ultimately form the basis for collaboration or licensing agreements between Lilly and external institutions.

"Each year, researchers throughout the world design and synthesize compounds in university and biotechnology laboratories that are never fully evaluated as potential drug candidates," said Alan D Palkowitz, vice president of discovery chemistry research and technologies at Lilly. "There's an untapped source of ideas and compounds in the greater scientific community that could ultimately impact patients' lives following further evaluation and development."

Such collaborations are not new, but PD2 aims to provide global external researchers with easier access to Lilly's drug discovery and development process, particularly for groups that may not have worked with Lilly before.

Through PD2, researchers confidentially submit a structure of their compound for initial computational evaluation using proprietary Lilly algorithms focused on drug-like properties and structural novelty. If the compound structure meets certain criteria, the researcher is then invited to submit a physical sample for biological testing. All testing by Lilly is free, and all intellectual property rights remain with the submitting researcher and/or institution at this stage.

After biological testing, Lilly provides the external researchers with a data report comprising a complete biological profile of the compound across the four assay modules. In return, Lilly has first rights to exclusively negotiate a collaboration or licensing agreement for promising compounds.

17th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics